Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease

Neurology

Volumn 68, Issue 2, 2007, Pages 99-109

  Kishnani, P S ^a   Corzo, D ^b   Nicolino, M ^c   Byrne, B ^d   Mandel, H ^e   Hwu, W L ^f   Leslie, N ^g   Levine, J ^h   Spencer, C ^d   McDonald, M ^a   Li, J ^a   Dumontier, J ^c   Halberthal, M ^e   Chien, Y H ^f   Hopkin, R ^g   Vijayaraghavan, S ⁱ   Gruskin, D ^j   Bartholomew, D ^a,k   Van Der Ploeg, A ^l   Clancy, J P ^m   Parini, R ⁿ   Morin, G ^o   Beck, M ^p   De La Gastine, G S ^q   Jokic, M ^q   Thurberg, B ^b   Richards, S ^b   Bali, D ^a   Davison, M ^r   Worden, M A ^b   Chen, Y T ^s   Wraith, J E ⁱ   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c HÔPITAL DEBROUSSE   (France)

^d UNIVERSITY OF FLORIDA   (United States)

^e RAMBAM MEDICAL CENTER   (Israel)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NATIONWIDE CHILDREN S HOSPITAL   (United States)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ SAN GERARDO HOSPITAL   (Italy)

^o AMIENS UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^q CHU CÔTE DE NACRE   (France)

^r Genzyme Corporation   (Netherlands)

^s INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

ABNORMAL RESPIRATORY SOUND; ADULT; AGITATION; ARTICLE; ARTIFICIAL VENTILATION; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; CYANOSIS; DEATH; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; FLUSHING; GASTROESOPHAGEAL REFLUX; GLYCOGEN STORAGE DISEASE TYPE 2; HEART RATE; HUMAN; HUMAN CELL; INDUCED HYPOTENSION; IRRITABILITY; LIVEDO RETICULARIS; MALE; MORTALITY; OXYGEN SATURATION; PALLOR; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PRURITUS; RESTLESSNESS; RETCHING; RIGOR; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TREATMENT OUTCOME; TREMOR; URTICARIA; VOMITING;

EID: 33846033132     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000251268.41188.04     Document Type: Article

References (27)

1. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3389-3420.
2. van den Hout HMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340.
3. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-288.
4. Chen YT, Amalfitano A. Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 2000;6:245-251.
5. Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000;137:283-285.
6. Kishnani PS, Hwu, W-L, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-676.
7. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
8. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-274.
9. Van den Hout JMP, Kamphoven JHJ, Winkel LPF, et al. Long-term intravenous treatment of Pompe's disease with recombinant human alpha glucosidase from milk. Pediatrics [serial online] 2004;113:448-457. Available at http://pediatrics.aappublications.org. Accessed August 1, 2006.
10. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31.
11. Kishnani PS, Nicolino M, Voit T, et al. Results from a phase II trial of Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease. J Pediatr 2006;149:89-97.
12. Piper MC, Darrah J. Motor assessment of the developing infant. Philadelphia: WB Saunders, 1994.
13. Feldman AB, Haley SM, Coryell J. Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 1990;70:602-610.
14. Haley SM, Fragala MA, Aseltine R, Ni P, Skriner AM. Development of a disease-specific disability instrument for Pompe disease. Pediatr Rehabil 2003;6:77-84.
15. Haley SM, Fragala-Pinkham MA, Ni PS, Skriner AM, Kaye EM. Pediatric physical functioning reference curves. Pediatr Neurol 2004;31:333-341.
16. Bayley N. Bayley Scales of Infant Development, 2nd ed. New York: Harcourt Brace, 1993.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958;53:457-481.
18. Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet 1978;30:132-143.
19. Cox DR. Regression models and life tables (with discussion). J R Statist Soc Ser 1972;B34:187-220.
20. Wandt B, Bojo L, Tolagen K, Wranne B. Echocardiographic assessment of ejection fraction in left ventricular hypertrophy. Heart 1999;82:192-198.
21. Kuczmarski RJ, Ogden LGrummer-Strawn LM, et al. CDC growth charts: United States. Advance data from vital and health statistics; no. 314. Hyattsville, MD: National Center for Health Statistics, 2000.
22. Kamphoven JH, de Ruiter MM, Winkel LP, et al. Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis 2004;16:14-20.
23. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398.
24. Brady RO, Murray GJ, Oliver KL, Leitman SF, Fleisher TA, Barton NW. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997;100:E11.
25. Ponce E, Moskovitz J, Grabowski GA. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid b-glucosidase. Blood 1997;90:43-48.
26. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-2088.
27. Zhao H, Bailey LA, Grabowski GA. Enzyme therapy of Gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 2003;30:90-96.